Study Evaluating the Safety and Efficacy of FOLFOX Plus Apatinib or FOLFIRI Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2018
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Carcinoma; Colorectal cancer
- Focus Therapeutic Use
- 05 Sep 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
- 05 Sep 2018 Planned initiation date changed from 1 Dec 2017 to 1 Dec 2019.
- 06 Nov 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.